Evaluation of tumor infiltrating lymphocytes (TILs) using humanized mouse model

O Shinichiro Tsunesumi, Hiroyuki Okada, Shigenori Enoki, Seiichi Katayama



Pharmacology Department, Nonclinical Research Center

COI Disclosure Information

Lead Presenter/Responsible Researcher:

Shinichiro Tsunesumi

I have no financial relationships to disclose.

Objective



In recent years, research and development of immunity checkpoint inhibitors have become active. HuNOG mice have a human immune system in part (humanized mice) and useful for preclinical immunotherapy research.

In this study, we examined the evaluation method for tumor infiltrating lymphocytes (TILs) using huNOG mice.

Materials and Methods



Animals

huNOG mice (Central Institute for Experimental Animals), ♀

Cancer cell line

Human breast cancer cell line: MDA-MB-231 (ATCC)

Administration substance

- Pembrolizumab (anti-PD-1 antibody): Selleck
- Human IgG4, kappa Isotype Control (control antibody): CrownBio

Equipment

- gentleMACS Octo Dissociator with Heaters: Miltenyi Biotec
- BD FACSLyric Flow Cytometer: BD Biosciences

Materials and Methods




Group configuration

Group	Dose	Number
Control	10 mg/kg	6
anti-PD-I antibody	10 mg/kg	6

Evaluation

- Tumor volume
- % of hCD4+, hCD8+, hCD4+FoxP3+ cells


Experiment Schedule



Results (1)



Anti-tumor effect of Pembrolizumab in MDA-MB-231 bearing-huNOG mice





Points, mean for 6 animals; vertical bars, S.E. * p<0.05 vs the control group (Student's t test).

Results (2)



Flow cytometric analysis of TILs





Columns, mean for 6 animals; vertical bars, S.E.

Conclusion



- Pembrolizumab was found to have antitumor effects in this model.
- hCD4 and hCD8 cells isolated from the tumor cells were observed like those in the spleen used as a measurement control.

These results indicated that an evaluation system for TILs has been successfully established in the huNOG mouse model under the present experimental condition.